Manning Lab
The Manning lab is defining the molecular connections between nutrient signaling and metabolic networks under both physiological and pathological states. Lab researchers are particularly focused on the role of the PI3K-mTOR signaling network in the control of cellular and systemic metabolism and its impact on the insulin response, type-2 diabetes, cancer, neurological disorders, and aging.
665 Huntington Ave
Building 2, Rm. 127
Boston, MA 02115
Disease Related Publications
Schrötter S, Yuskaitis CJ, MacArthur MR, Mitchell SJ, Hosios AM, Osipovich M, Torrence ME, Mitchell JR, Hoxhaj G, Sahin M, Manning BD. The non-essential TSC complex component TBC1D7 restricts tissue mTORC1 signaling and brain and neuron growth. Cell Rep. 2022 May 17;39(7):110824. doi: 10.1016/j.celrep.2022.110824. PMID: 35584673; PMCID: PMC9175135.
Valvezan AJ, McNamara MC, Miller SK, Torrence ME, Asara JM, Henske EP, Manning BD. IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex. JCI Insight. 2020 Apr 9;5(7):e135071. doi: 10.1172/jci.insight.135071. PMID: 32271165; PMCID: PMC7205253.
Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020 Feb;20(2):74-88. doi: 10.1038/s41568-019-0216-7. Epub 2019 Nov 4. PMID: 31686003; PMCID: PMC7314312.
Valvezan AJ, Turner M, Belaid A, Lam HC, Miller SK, McNamara MC, Baglini C, Housden BE, Perrimon N, Kwiatkowski DJ, Asara JM, Henske EP, Manning BD. mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a Targetable Metabolic Vulnerability. Cancer Cell. 2017; pii: S1535-6108(17)30417-8. PMID: 29056426
Manning BD. Game of TOR – The Target of Rapamycin Rules Four Kingdoms. N Engl J Med. 2017; 377(13):1297-9. PMID: 28874074
Ilagan E, Manning BD. Emerging role of mTOR in the response to cancer therapeutics. Trends Cancer 2016; 2:241-251. PMID:27668290
Housden BE, Valvezan AJ, Kelley C, Sopko R, Hu Y, Roesel C, Lin S, Buckner M, Tao R, Yilmazel B, Mohr SE, Manning BD, Perrimon N. Identification of potential drug targets for tuberous sclerosis complex by synthetic screens combining CRISPR-based knockouts with RNAi. Sci Signal. 2015; 8(393):rs9. PMID: 26350902
Kwiatkowski DJ and Manning BD. The molecular basis of giant cells in tuberous sclerosis complex. N. Engl J Med 2014; 371(8):778-80. PMID: 25140966
Menon S, Yecies JL, Zhang HH, Howell JJ, Nicholatos J, Harputlugil E, Bronson RT, Kwiatkowski DJ, Manning BD. Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci Signal. 2012; 5(217):ra24. PMID: 22457330
Huang J, Wu S, Wu CL, and Manning BD. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res. 2009; 69(15):6107-14. PMID: 19602587
Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC. Feedback inhibition of Akt signaling limits the growth of tumors lacking TSC2. Genes Dev. 2005; 19(15):1773-8. PMID: 16027169